Hope and hype

December 1998
Network Magazine of the Canadian Women's Health Network;Winter1998/1999, Vol. 2 Issue 1, p3
Academic Journal
Relates how the author decided to go on combination therapy to combat HIV-related symptoms. Author's initial refusal to take any AIDS drugs; Details of how the author reached the decision to try a combination of AIDS drugs; Author's daily medication routine; Effects of the combination therapy.


Related Articles

  • Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine. Coplan, Paul M.; Cook, John R.; Carides, George W.; Heyse, Joseph F.; Wu, Albert W.; Hammer, Scott M.; Nguyen, Bach-Yen; Meibohm, Anne R.; DiNubile, Mark J. // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p426 

    Objective. in AIDS Clinical Trial Group (ACTG) study 320, triple-combination antiretroviral therapy including indinavir significantly slowed progression to acquired immunodeficiency syndrome or death, compared with treatment with dual nucleoside reverse-transcriptase inhibitors (NRTIs) alone, in...

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

  • Does HCV make HIV infection worse? Mascolini, Mark // Research Initiative/Treatment Action!;Summer2014, Vol. 19 Issue 1, p20 

    The article discusses impact of hepatitis C virus (HCV) infection on HIV infection. Topics discussed include impact of HCV infection on mortality of HIV people, on response to combination antiretroviral therapy (cART), and on clinical outcomes and progression to AIDS. Two U.S. studies on HCV/HIV...

  • HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. Treviño, Ana; Soriano, Vicente; Poveda, Eva; Parra, Patricia; Cabezas, Teresa; Caballero, Estrella; Roc, Lourdes; Rodríguez, Carmen; Eiros, Jose M.; Lopez, Mariola; De Mendoza, Carmen // Journal of Antimicrobial Chemotherapy (JAC);Aug2014, Vol. 69 Issue 8, p2191 

    Background HIV-2 infection is characterized by low plasma viraemia and slower progression to AIDS in comparison with HIV-1 infection. However, antiretroviral therapy in patients with HIV-2 is less effective and often fails to provide optimal CD4 recovery. Methods We examined viral tropism in...

  • Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a 47-year-old, Caucasian woman who developed Buffalo Hump at the time of antiretroviral therapy which includes raltegravir and unboosted atazanavir for treating Human Immunodeficiency virus (HIV)-1 infection. It informs that the diagnosis revealed that the...

  • Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Jain, Vivek; Hartogensis, Wendy; Bacchetti, Peter; Hunt, Peter W.; Hatano, Hiroyu; Sinclair, Elizabeth; Epling, Lorrie; Lee, Tzong-Hae; Busch, Michael P.; McCune, Joseph M.; Pilcher, Christopher D.; Hecht, Frederick M.; Deeks, Steven G. // Journal of Infectious Diseases;Oct2013, Vol. 208 Issue 8, p1202 

    Background. CD4+/CD8+ T-cell activation levels often remain elevated in chronic human immunodeficiency virus (HIV) infection despite initiation of antiretroviral therapy (ART). T-cell activation predicts early death and blunted CD4+ T-cell recovery during ART and may affect persistent HIV...

  • Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Bernardini, Claudia; Maggiolo, Franco // Patient Preference & Adherence;2013, Vol. 7, p531 

    The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food...

  • Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment. Roux, Perrine; Carrieri, M. Patrizia; Cohen, Julien; Ravaux, Isabelle; Poizot-Martin, Isabelle; Dellamonica, Pierre; Spire, Bruno // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, p1433 

    Background. The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year...

  • Discontinuation of Prophylaxis against. El-Sadr, Wafaa M.; Burman, William J.; Grant, Lisa Bjorling; Matts, John P.; Hafner, Richard; Crane, Lawrence; Zeh, Doug; Gallagher, Barbara; Mannheimer, Sharon B.; Martinez, Ana; Gordin, Fred // New England Journal of Medicine;04/13/2000, Vol. 342 Issue 15, p1085 

    Background: Several agents are effective in preventing Mycobacterium avium complex disease in patients with advanced human immunodeficiency virus (HIV) infection. However, there is uncertainty about whether prophylaxis should be continued in patients whose CD4+ cell counts have increased...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics